Biotech News
Taiho Pharmaceutical Expands ADC Capabilities with Araris Biotech Acquisition
Taiho Pharmaceutical Co., Ltd. has announced a definitive agreement to acquire Araris Biotech AG, a Swiss biotechnology company specialising in next-generation antibody-drug conjugates (ADCs). The deal includes an upfront payment of $400 million, with potential milestone-based payments of up to $740 million. The acquisition
18 March 2025